EP1937220A2 — Ramipril formulation with increased stability
Assigned to Selamine Ltd · Expires 2008-07-02 · 18y expired
What this patent protects
A pharmaceutical formulation contains ramipril principally in the form of a ramipril salt and is buffered at basic pH. Ramipril in the formulation degrades preferentially to the diacid, ramiprilat, rather than the diketopiperazine.
USPTO Abstract
A pharmaceutical formulation contains ramipril principally in the form of a ramipril salt and is buffered at basic pH. Ramipril in the formulation degrades preferentially to the diacid, ramiprilat, rather than the diketopiperazine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.